(Plerixafor + tacrolimus) is under clinical development by MedRegen and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I drugs for Transplant Rejection have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Plerixafor + tacrolimus)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Plerixafor + tacrolimus) overview
MRG-001 is under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome, alcoholic hepatitis, amyotrophic lateral sclerosis (ALS), wounds acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), diabetic nephropathy, spinal cord injury, brain injury, keloid scars, inflammatory bowel disease (IBD), organ transplantation, acute liver failure, MASH, myocardial infarction, corneal injury and atherosclerosis. It is administered through subcutaneous route. The drug is a fixed dose combination of plerixafor, targeting CXCR4 and the tacrolimus targeting peptidyl prolyl cis trans isomerase FKBP4.
MedRegen overview
MedRegen is developing novel therapeutics for the treatment of different types of organs and tissue injury. The company is headquartered in Baltimore, Maryland, the US.
For a complete picture of (Plerixafor + tacrolimus)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
